BioSpace News Archive

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has signed an agreement with a leading clinical quality and validation processes consultancy to oversee the preparation and submissi

A Research Collaboration Between LuminUltra, Dalhousie University and Halifax Water Demonstrates Wastewater Data Is a Powerful Tool in Early Detection and Tracking COVID-19 Prevalence within Communities

Akili today announced multiple data presentations on EndeavorRxTM (see prescribing information below), including results from the STARS-Adjunct trial, a multi-site open-label study designed to evaluate the impact of EndeavorRx™ on impairments in daily life in children with attention-deficit/hyperactivity disorder (ADHD) and inform prescribing practices.

Tuesday marked the official opening of Minnesota’s new COVID-19 saliva testing lab in Oakdale, Minnesota. Governor Tim Walz toured the lab and highlighted the importance of testing to the state’s comprehensive strategy to combat COVID-19.

Day Zero Diagnostics, Inc., an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced results from multiple studies evaluating Day Zero’s new class of diagnostics that are intended to help physicians quickly and accurately diagnose and treat life-threatening bacterial infections.

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020.

Exergen Corporation Launches Nurse Support Program to Ensure Every Nurse Has Access to an Accurate Thermometer at Home to Protect Themselves and Their Families

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, announced today that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA).

Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it has filed a method of use patent with the U.S. Patent and Trademark Office covering the use of Fatty Acid Binding Protein 5 (FABP5) inhibitors for the treatment of psychological disorders s

Aiforia, a leading provider of deep learning artificial intelligence (AI) solutions for image analysis across a variety of medical domains, announces its newly formed Scientific Advisory Board.